NASDAQ:ABUS - Arbutus Biopharma Stock Price, Forecast & News

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Arbutus Biopharma Corp (NASDAQ:ABUS) issued its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.22. The biopharmaceutical company had revenue of $3.10 million for the quarter, compared to analyst estimates of $9.85 million. Arbutus Biopharma had a negative return on equity of 298.87% and a negative net margin of 2,416.39%. View Arbutus Biopharma's Earnings History.

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Arbutus Biopharma.

3 brokerages have issued 12-month target prices for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $6.00. On average, they expect Arbutus Biopharma's stock price to reach $5.50 in the next year. This suggests a possible upside of 79.2% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arbutus Biopharma.

News coverage about ABUS stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Arbutus Biopharma earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Arbutus Biopharma.

Arbutus Biopharma saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 571,100 shares, a drop of 38.3% from the December 15th total of 924,900 shares. Based on an average daily trading volume, of 697,800 shares, the short-interest ratio is presently 0.8 days. Currently, 1.5% of the company's stock are short sold. View Arbutus Biopharma's Current Options Chain.

Some companies that are related to Arbutus Biopharma include Frequency Therapeutics (FREQ), ANI Pharmaceuticals (ANIP), Cytokinetics (CYTK), Basilea Pharmaceutica (BPMUF), Urogen Pharma (URGN), Retrophin (RTRX), Cara Therapeutics (CARA), DiaMedica Therapeutics (DMCAF), Processa Pharmaceuticals (PCSA), ImmunoGen (IMGN), Omeros (OMER), Flexion Therapeutics (FLXN), Emisphere Technologies (EMIS), Axovant Sciences (AXON) and Vectura Group (VEGPF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), Alibaba Group (BABA), Arrowhead Pharmaceuticals (ARWR), NewLink Genetics (NLNK), GoPro (GPRO), Inovio Pharmaceuticals (INO) and ACADIA Pharmaceuticals (ACAD).

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABUS stock can currently be purchased for approximately $3.07.

Arbutus Biopharma has a market capitalization of $190.68 million and generates $5.90 million in revenue each year. The biopharmaceutical company earns $-57,060,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Arbutus Biopharma employs 79 workers across the globe.View Additional Information About Arbutus Biopharma.

The official website for Arbutus Biopharma is http://www.arbutusbio.com/.

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]